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Abstract 
Background 
Corticotropin-releasing factor type 2 receptors (CRFR2) are suggested to facilitate successful 
recovery from stress to maintain mental health. They are abundant in the midbrain raphe 
nuclei, where they regulate serotonergic neuronal activity and have been demonstrated to 
mediate behavioural consequences of stress. Here, we describe behavioural and serotonergic 
responses consistent with maladaptive recovery from stressful challenge in CRFR2-null mice. 
Results 
CRFR2-null mice showed similar anxiety levels to control mice before and immediately after 
acute restraint stress, and also after cessation of chronic stress. However, they showed 
increased anxiety by 24 hours after restraint, whether or not they had been chronically 
stressed. 
Serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) contents were quantified and the 
level of 5-HIAA in the caudal dorsal raphe nucleus (DRN) was increased under basal 
conditions in CRFR2-null mice, indicating increased 5-HT turnover. Twenty-four hours 
following restraint, 5-HIAA was decreased only in CRFR2-null mice, suggesting that they 
had not fully recovered from the challenge. In efferent limbic structures, CRFR2-null mice 
showed lower levels of basal 5-HT in the lateral septum and subiculum, and again showed a 
differential response to restraint stress from controls. 
Local cerebral glucose utilization (LCMRglu) revealed decreased neuronal activity in the 
DRN of CRFR2-null mice under basal conditions. Following 5-HT receptor agonist 
challenge, LCMRglu responses indicated that 5-HT1A receptor responses in the DRN were 
attenuated in CRFR2-null mice. However, postsynaptic 5-HT receptor responses in forebrain 
regions were intact. 
Conclusions 
These results suggest that CRFR2 are required for proper functionality of 5-HT1A receptors in 
the raphe nuclei, and are key to successful recovery from stress. This disrupted serotonergic 
function in CRFR2-null mice likely contributes to their stress-sensitive phenotype. The 5-HT 
content in lateral septum and subiculum was notably altered. These areas are important for 
anxiety, and are also implicated in reward and the pathophysiology of addiction. The role of 
CRFR2 in stress-related psychopathologies deserves further consideration. 
Keywords 
5-HT1A receptor, anxiety, corticotropin-releasing factor type 2 receptor, raphe nuclei, 
serotonin, stress 
Background 
Serotonin (5-HT) is a key neurotransmitter in the control of mood. It is the major target of 
current antidepressant medications, and often also of treatments for anxiety disorders [1,2]. 
The principal sources of 5-HT neurons projecting to the forebrain are the midbrain dorsal 
(DRN) and median (MRN) raphe nuclei [3,4]. 
Corticotropin-releasing factor (CRF) is a key mediator of the stress response [5-7], and 
anxiety and affective disorders have been associated with CRF hyperactivity [8]. 
Corticotropin-releasing factor receptors are abundant in both DRN and MRN [9-11], where 
they are expressed in serotonergic and non-serotonergic neurons, including regulatory 
GABAergic neurons [12,13], suggesting the potential for complex interactions between CRF 
and serotonergic systems. Electrophysiological studies show that exogenous CRF 
administered to the raphe modulates serotonergic neuronal firing activity [14-16], and 
therefore CRF receptor-mediated effects on stress-related behaviours may be mediated via 5-
HT in vivo [17-20]. 
Type 1 (CRFR1) and type 2 (CRFR2) CRF receptors [21-23] are preferentially activated by 
CRF or urocortin neuropeptides (Ucn1, Ucn2, Ucn3), respectively [24-28]. The raphe nuclei 
receive inputs from both CRF and Ucn1 expressing neurons [14,15,29-31], and a potentially 
important role for the CRF system in controlling 5-HT neurons here is emerging. 
CRFR2 is expressed at high levels in the raphe nuclei, while CRFR1 is expressed at lower 
levels in the raphe nuclei in rats and appears to be absent from this area in mice and human 
beings [9-11]. Exogenously administered CRFR2 agonists induce c-Fos expression in DRN 
5-HT neurons, increase their firing rate, and increase 5-HT release in efferent stress-related 
nuclei [32-36]. In pharmacological studies, CRFR2 activation in the DRN potentiates 
immediate fear responses [35], fear conditioning and escape deficits 24 hours later in a model 
of learned helplessness [37,38], and decreases exploratory behaviours [19] in rodents. 
Recently, altered anxiety-like behaviour in Ucn-knockout or Ucn-overexpressing mice has 
been linked to disturbances in serotonergic activity in the neural circuitry controlling anxiety 
[39-41]. The Ucn1/Ucn2/Ucn3 triple knockout mouse phenotype suggests that CRFR2 and 
particularly Ucn3 are involved in successful recovery from stress [41]. This interaction with 
the 5-HT system may provide a major link between the two main arms of the central stress 
response; the CRF/Ucns peptidergic pathways and the sympathetic monoaminergic system. 
5-HT1A receptors (5-HT1AR) are also particularly associated with modulating anxiety [42] 
and pharmacological stimulation of CRF receptors in the raphe nuclei has been demonstrated 
to regulate serotonergic neuronal firing here [43,44]. Thus, CRF-containing neuronal 
projections from the central amygdala (CeA) to the raphe nuclei [45] may modulate activity 
at postsynaptic 5-HT1AR by directly regulating activity of efferent 5-HT projections or may 
have wider-ranging effects on 5-HT function via altered raphe 5-HT1AR autoreceptor activity. 
Conversely, 5-HT1AR activity can influence CRF-induced changes in behaviour; 5-HT1AR-
selective agonists can attenuate CRF-induced grooming [46]. We have previously shown that 
5-HT1AR responsiveness plays a key role in stress-related behaviours associated with chronic 
activation of CRFR2 [39] and that interaction is further explored in the studies presented 
here. 
Activation of CRFR2 affects anxiety-like behaviour under stressed conditions [47-49] and 
CRFR2-null mice have an anxiogenic phenotype [50,51]. This raises the question of what 
role CRFR2 might play in the pathophysiology of anxiety-related and affective disorders in 
human beings. To further investigate the mechanisms underlying this, we examined the 
anxiety phenotype of CRFR2-null mice in detail, and characterized their serotonergic 
responses to stress. 
Methods 
Animals 
Mice were housed in temperature- and lighting-controlled rooms (lights on, 12 h) with free 
access to laboratory chow and water. CRFR2-null mice, as previously described [50], and 
control littermates (C57BL6 × 129) were the adult male offspring of parents heterozygous for 
the knockout allele. For CRFR2 mRNA studies, adult male wild type C57BL6/J mice (Harlan 
Laboratories) were used. Mice were group housed, except for the chronic variable mild stress 
(CVMS) protocols, for which they were singly housed. Principles of laboratory animal care 
(NIH No. 85-23, 1985) were followed. All procedures were approved by The Weizmann 
Institute Animal Use and Care Committee or the United Kingdom Animals (Scientific 
Procedures) Act, 1986. 
Behavioural testing 
Tests were carried out during the dark phase of the light cycle on adult male mice (2 to 4 
months). Mice were habituated in the home cage in a dark room for 2 hours prior to each 
behavioural test. Separate groups of mice were tested under: (a) basal conditions with no 
stress applied prior to testing, n = 12 for control group, n = 14 for CRFR2-null group; (b) 
immediately following 30 min of acute restraint stress (ARS), n = 13, both groups; (c) 24 to 
48 hours following ARS, n = 5 for control group, n = 8 for CRFR2-null group (light/dark 
transfer test performed at 24 hours post-stress, open-field at 48 hours post-stress); (d) 3 to 4 
days following a 4-week CVMS protocol, (light/dark transfer test performed at 3 days post-
stress, open-field at 4 days post-stress), n = 10 for control group, n = 11 for CRFR2-null 
group. The mice of group d were then retested 3 weeks later, when an ARS was applied and 
testing was performed at 24 to 48 hours. Figure 1 shows the timeline of the experimental 
protocols with stress procedures. 
Figure 1 Schematic representation of experimental protocols and timelines. (A) Separate 
cohorts of CRFR2-null and control mice were tested for anxiety-like behaviour in the 
light/dark transfer and open-field tests: under basal conditions; immediately following ARS; 
following CVMS and again 24 to 48 h after an ARS applied 3 weeks after the end of CVMS; 
24 to 48 h following ARS. (B) CRFR2-null and control mice were exposed to no stress, ARS 
or CVMS, and mRNA expression of stress-related genes and serotonin transporter (SERT) 
binding were quantified 12 h after the end of stress. 5-HT/5HIAA content in brain nuclei 
were quantified in unstressed mice and 24 h after ARS. (C) LCMRglu was measured in 
CRFR2-null and control mice one hour after administration of saline or 5-HTR agonist. (D) 
CRFR2 mRNA levels in brain were quantified over a 48-h time course following ARS or 7 
days after CVMS in control mice. , ARS; , CVMS; d, days; w, weeks. 
Open-field (OF) test 
The apparatus and experimental conditions were as previously described [50]. Mice were 
placed in the centre of the apparatus to initiate a 10-min test session. Visits to, and distance 
travelled and time spent in the inner zone of the arena were quantified using a video tracking 
system (VideoMot2; TSE Systems, Bad Hamburg, Germany). 
Light/dark transfer test (LDT) 
Apparatus and experimental conditions were as previously described [50]. During a 5-min 
test session, visits to, and distance travelled and time spent in the light compartment were 
measured. 
Stress procedures 
Mice were subjected to 30 min ARS in a ventilated 50 ml plastic centrifuge tube. The CVMS 
regime was modified from Ducottet et al. [52]. Mice were singly housed and a variety of mild 
stressors were applied on an unpredictable schedule, 2 to 3 stressors per day for 4 weeks; 
these included disruptions to the light-dark cycle, cage shift to one previously inhabited by 
another male, cage tilt, damp bedding, low-intensity stroboscopic illumination, white noise, 
restraint stress, short periods of food or water restriction, and housing with no bedding 
followed by water in the cage. Controls were housed under stress-free conditions. 
In the CVMS paradigm, mice were behaviourally tested 48 hours following termination of 
the last stressor, which was standardized and was 24 hours of constant light for all mice (n = 
10 or 11). For in-situ hybridization and 5-HT transporter (SERT) binding studies, mice (n = 6 
for control basal group, n = 8 for CRFR2-null basal group, n = 7 for all stress groups) were 
killed 12 hours after ARS, or after the last variable stressor, by decapitation within 15 s of 
disturbing the home cage. The brains were removed, rapidly frozen on dry ice and stored at 
−80°C until analysis. 
Local cerebral glucose utilization (LCMRglu) 
Local cerebral glucose utilization (LCMRglu) was determined as described previously 
[39,53]. Mice (n = 8, all groups) were injected (intraperitoneally) with either 10 mg kg-1 8-
hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT), 25 mg kg-1 1-(2,5-dimethoxy-4-
iodophenyl)-2-aminopropane (DOI) or vehicle (0.1 ml 0.9% NaCl). At 10 min after 8-OH-
DPAT, or 20 min after DOI, 5 µCi [14C]-2-deoxyglucose in 0.4 ml 0.9% NaCl was injected 
intraperitoneally. After 45 min, mice were decapitated and their brains analyzed by 
quantitative autoradiographic imaging, as described previously [54,55]. 
Analysis of tissue concentrations of 5-HT and 5-HIAA 
Mice (n = 7 for unstressed groups, n = 6 for ARS groups) were killed by decapitation under 
basal conditions or 24 hours following ARS. Brains were stored at −80°C until analysis. 
Areas selected for microdissection were identified by comparison with a standard mouse 
brain stereotaxic atlas [56]. To ensure accuracy, we used a stereomicroscope to visualize 
neuroanatomical landmarks for use as reference points in identifying specific nuclei and 
subdivisions of the DRN. Small diameter microdissection tools (310 to 410 µm diameter) 
were used to restrict dissections to the subregion of interest. High-pressure liquid 
chromatography analysis of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) was performed, 
as previously described [57]. 
CRFR2 mRNA qPCR analysis 
Quantitative PCR for CRFR2 mRNA expression was carried out as previously reported [40] 
in brain taken from naïve mice (controls), or 3, 6, 12, 24 or 48 hours after ARS, or, for 
CVMS mice, one week after the end of the stress protocol (n = 8 all groups) 
In-situ hybridization (ISH) histochemistry 
Coronal brain sections (10 µm) were cut on a cryostat, thaw-mounted onto silanized glass 
slides, and stored at −80°C until use. In-situ hybridization procedures and probes were as 
previously described [58-60]. Plasmids (generous gifts from Professor M. Holmes and Dr V. 
Bombail) containing cDNA fragments for glucocorticoid receptor (GR), mineralocorticoid 
receptor (MR), 5-HT1A R, 5-HT2CR and tryptophan hydroxylase 2 (TPH2) were used to 
generate 35S-UTP-labelled specific antisense probes to mRNAs. Following ISH, slides were 
dipped in Kodak Autoradiography Emulsion (Molecular Imaging Systems, New York, USA) 
and exposed at 4°C for between 24 h and 6 weeks, depending on the probe, developed and 
counterstained. The hybridization signal for each brain area was determined using computer-
assisted grain counting software (Zeiss KS 300 3.0, Carl Zeiss Vision, GmbH). For each 
animal, silver grains were counted in a fixed circular area over 6 to 10 individual neurons per 
subregion. The background, counted over areas of white matter, was subtracted. Analysis was 
carried out blind to treatment group. 
5-HT transporter (SERT) binding 
Serotonin transporter (SERT) binding was determined on brain sections, cut as above, using 
(3H)-paroxetine (Perkin Elmer, UK) as previously described [61]. Slides were then exposed 
to (3H)-sensitive film (Amersham Hyperfilm MP, GE Healthcare, UK) at −80°C for 6 weeks. 
Analysis of autoradiographs was performed by measuring the signal over the area of interest 
with densitometry software (MCID Basic 7.0, Imaging Research, Inc.). The background was 
subtracted. 
Statistical analyses 
Statistical analyses employed the two-tailed Student’s t test or two-way analysis of variance 
(ANOVA) with post-hoc analysis using Fisher’s protected least significant difference test as 
appropriate, with the exception of time course of CRFR2 expression, where one-way 
ANOVA with Dunnett’s post-hoc analysis was used. Data are presented as mean ± standard 
error of the mean (SEM). Differences were considered statistically significant at P < 0.05. 
Results 
CRFR2-null mice show increased anxiety 24 to 48 h after acute restraint stress 
(ARS) 
Under basal conditions, where mice were not exposed to stress (other than that caused by the 
test itself), CRFR2-null mice and littermate controls showed no differences in anxiety-related 
behaviour in two well-validated behavioural tests, the LDT (Figure 2) and the OF test (Figure 
3), compared with littermate controls. 
Figure 2 CRFR2-null mice exhibit increased anxiety-like behaviour 24 hours after ARS 
in the LDT. Under basal conditions (A), immediately following ARS (B), or after CVMS 
(C), no differences were observed in behaviour between CRFR2-null mice and controls. 
However, when CVMS mice (D) or naïve mice (E) were exposed to ARS and tested 24 to 48 
hours later, CRFR2-null mice showed increased anxiety-like behaviour compared with 
control mice. Data expressed as mean ± SEM. N = 10 to 14 for A-D, N = 5 to 8 for E. * P < 
0.05, ** P < 0.01, ~ P = 0.53, compared with control. 
Figure 3 CRFR2-null mice exhibit increased anxiety-like behaviour 48 hours after ARS 
in the OF test. Under basal conditions (A), immediately following ARS (B), or after CVMS 
(C), no differences were observed in behaviour between CRFR2-null mice and controls. 
However, when CVMS mice (D) or naïve mice (E) were exposed to ARS and tested 24 to 48 
h later, CRFR2-null mice showed increased anxiety-like behaviour compared with control 
mice. Data expressed as mean ± SEM. N = 10 to 14 for A-D, N = 5 to 8 for E. * P < 0.05, ** 
P < 0.01, *** P < 0.001, ~ P = 0.085, compared with control. 
Because this finding contrasted with previous reports [50,51], we hypothesized that stressful 
challenge was required to reveal the role of CRFR2 in anxiety. Another group of mice was 
tested immediately following 30 min ARS. Again, no effect of genotype on anxiety-like 
behaviour was observed (Figures 2 and 3). A further cohort of mice exposed to CVMS was 
tested 3 to 4 days after the end of the protocol, to allow for recovery from the final acute 
stressor, and again no differences were observed between control and CRFR2 mice in either 
behavioural test. 
However, 3 weeks later, these same CVMS mice were exposed to a single 30-min ARS, and 
24 to 48 h later the CRFR2-null mice showed significantly increased indices of anxiety 
compared with controls, with fewer visits to (t = 3.022, P = 0.007, n = 10 or 11), shorter 
distance travelled in (t = 2.360, P = 0.029, n = 10 or 11), and a trend to less time spent in the 
light chamber in the LDT (t = 2.062, P = 0.053, n = 10 or 11) (Figure 2), and fewer visits to 
the centre of (t = 2.271, P = 0.036, n = 10 or 11) and less time spent in (t = 2.231, P = 0.039, 
n = 10 or 11) the centre and a trend to less time spent in the OF test (t = 1.825, P = 0.085, n = 
10 or 11) (Figure 3). 
We then examined whether this delayed effect of ARS on anxiety was dependent on prior 
CVMS by subjecting a further cohort of mice to ARS alone, and observed the same increased 
anxiety-like behaviour 24 to 48 hours post-stress (Figures 2 and 3). In the LDT, CRFR2-null 
mice spent less time (t = 2.650, P = 0.023, n = 5 to 8) and travelled a shorter distance (t = 
2.833, P = 0.016, n = 5 to 8) in the light chamber. In the OF test, CRFR2-null mice spent less 
time in (t = 2.675, P = 0.022, n = 5 to 8) and made fewer visits to the centre (t = 3.604, P = 
0.004, n = 10 to 11), and travelled a shorter distance (t = 5.078, P = 0.0004, n = 10 to 11). 
Serotonergic function is altered in the raphe nuclei of CRFR2-null mice 
CRFR2 in the raphe nuclei modulate 5-HT activity, with consequences for stress-related 
behaviours [32-38]. Therefore serotonergic functions were examined in CRFR2-null and 
control mice. Neuronal metabolic activity, as measured by LCMRglu, was lower in both the 
DRN (t = 2.626, P = 0.048, n = 8 for 8-OH-DPAT experiment, t = 2.804, P = 0.036, n = 8 for 
DOI experiment) and median raphe nucleus (MRN) (t = 2.472, P = 0.049, n = 8 for 8-OH-
DPAT experiment, t = 2.785, P = 0.038, n = 8 for DOI experiment) of CRFR2-null mice as 
compared with controls under basal conditions (Figure 4). 
Figure 4 Serotonergic function is altered in the raphe nuclei of CRFR2-null mice. (A-E) 
LCMRglu in the dorsal raphe nucleus (DRN) and median raphe nucleus (MRN) is lower in 
CRFR2-null mice than controls under basal conditions. (A,C) 8-OH-DPAT or (B,D) DOI 
administration decreased LCMRglu in the (A,B) DRN or (C,D) MRN only in control mice. 
(E) Colour-coded autoradiograms from coronal brain sections at the level of the midbrain 
raphe. ‘Warm’ colours represent high levels of [14C]-2-deoxyglucose accumulation while 
‘cold’ colours represent low tracer accumulation. Images were selected from animals with 
matched plasma tracer and glucose concentrations. 5-HIAA and 5-HT content of the (F) 
dorsal and (G) caudal subdivisions of the DRN showed that the 5-HIAA:5-HT ratio was 
higher in CRFR2-null mice under basal conditions in the dorsal DRN (DRD) and was 
lowered by ARS only in CRFR2-null mice in both DRD and caudal DRN (DRC). Data 
expressed as mean ± SEM. N = 8 for LCMRglu, ANOVA critical F(1,28) value = 4.196 for P ≤ 
0.05, 7.636 for P ≤ 0.01, 13.500 for P ≤ 0.001. N = 6 or 7 for 5-HIAA and 5-HT content, 
ANOVA critical F(1,22) values = 4.301 for P ≤ 0.05, 7.945 for P ≤ 0.01, 14.380 for P ≤ 0.001. 
* P < 0.05, ** P < 0.01 in post-hoc analysis. 
Following challenge with the 5-HT1AR-specific agonist 8-OH-DPAT, a main effect of 
treatment (ANOVA: F(1,28) = 4.558, P = 0.044), and an interaction between genotype and 
treatment was observed in DRN (ANOVA: F(1,28) = 5.953, P = 0.021) (Figure 4). Post-hoc 
analysis revealed that controls responded with decreased LCMRglu in both the DRN (t = 
3.235, P = 0.0124, n = 8) and the MRN (t = 2.520, P = 0.047, n = 8) as expected, whereas the 
raphe nuclei of CRFR2-null mice were unresponsive to 5-HT1AR agonist. Following 5-HT2R-
specific agonist DOI challenge, only a main effect of genotype was seen in both the DRN 
(ANOVA: F(1,28) = 5.224, P = 0.030) and the MRN (ANOVA: F(1,28) = 5.333, P = 0.029). The 
pattern of responses was, however, the same as for 8-OH-DPAT. 
Studies to date have largely concentrated on the role of the DRN in respect to behaviour and 
anxiety. Therefore, we measured 5-HT and 5-HIAA within subregions of the DRN (Figure 
4). Within the caudal DRN, there was a main effect of genotype on 5-HIAA (ANOVA: F(1,22) 
= 7.094, P = 0.014) and a genotype X ARS interaction on 5-HIAA:5-HT ratio (ANOVA: 
F(1,22) = 6.153, P = 0.021). Post-hoc analysis revealed an increase in 5-HIAA (t = 3.472, P = 
0.002, n = 7) and 5-HIAA:5-HT ratio (t = 3.242, P = 0.004, n = 7) in CRFR2-mice under 
basal conditions, indicating increased serotonin turnover here. 24 hours following ARS, both 
the caudal (t = 2.759, P = 0.011, n = 6 or 7) and the dorsal (t = 4.087, P = 0.0005, n = 6 or 7) 
DRN showed decreases in 5-HIAA:5-HT ratio in CRFR2-null mice, with an associated 
decrease in 5-HIAA in the caudal DRN of CRFR2-null mice (t = 2.554, P = 0.018, n = 6 or 
7), whereas controls showed no effect of ARS on these parameters. 
5-HT responses to stress and 5-HTR agonists are altered in efferent brain 
regions of CRFR2-null mice 
Following challenge with the 5-HT1AR-specific agonist 8-OH-DPAT, there was a main effect 
of treatment throughout the forebrain (ANOVA: F(1,28) = 4.196 for P = 0.05) (Table 1) with a 
genotype x 8-OH-DPAT interaction observed in some extrapyramidal and limbic structures. 
Post-hoc analysis revealed that while controls had decreased LCMRglu in response to 8-OH-
DPAT in extrapyramidal regions as expected, CRFR2-null mice showed no response. These 
areas receive projections from the DRN but lack their own 5-HT1AR, indicating that this 
reflects attenuated DRN response to 5-HT1AR agonist. 
Table 1 LCMRglu in efferent brain regions of control and CRFR2-null mice in response to 5-HT1AR or 5-HT2R agonist 
 Control CRFR2-null Control CRFR2-null 
 Saline 8-OH-DPAT % Saline 8-OH-DPAT % Saline DOI % Saline DOI % 
Neocortex             
Frontal 46 ± 3 33 ± 3* −28 47 ± 3 42 ± 3* −21 a 47 ± 3 38 ± 2* −19 45 ± 2 30 ± 2* −33 a, b 
Anterior cingulate 48 ± 3 35 ± 2* −27 49 ± 2 39 ± 4* −35 a 50 ± 3 40 ± 2* −15 51 ± 3 34 ± 2* −33 a 
Prefrontal 47 ± 3 35 ± 3* −26 47 ± 3 42 ± 2 −6 a 50 ± 3 39 ± 3* −22 50 ± 3 30 ± 2* −40 a 
Somatosensory 55 ± 2 33 ± 4* −40 51 ± 4 45 ± 3* −22 a 56 ± 2 53 ± 3 −5 55 ± 4 44 ± 3* −20 a 
Parietal 53 ± 2 35 ± 2* −34 50 ± 4 43 ± 3 −21 a 55 ± 2 45 ± 1* −18 54 ± 3 37 ± 2* −31 a, b 
Hippocampus             
Subiculum 40 ± 3 26 ± 3* −35 45 ± 3 23 ± 3* −49 a 42 ± 2 43 ± 3 2 43 ± 3 33 ± 3* −23 
Dentate gyrus 26 ± 3 16 ± 3* −38 30 ± 2 15 ± 3* −50 a 28 ± 3 18 ± 2* −36 27 ± 3 16 ± 2* −14 a 
CA1 37 ± 3 22 ± 4* −41 38 ± 3 16 ± 2* −58 a 36 ± 3 26 ± 3* −28 37 ± 2 26 ± 2* −30 a 
CA2 35 ± 3 20 ± 3* −43 36 ± 3 19 ± 2* −47 a 35 ± 3 34 ± 3 −3 36 ± 3 29 ± 2* −19 
CA3 38 ± 2 20 ± 2* −47 41 ± 2 17 ± 2* −58 a 36 ± 2 28 ± 3 −22 36 ± 2 22 ± 3* −39 a 
Extrapyramidal areas             
Medial striatum 43 ± 3 33 ± 2* −23 42 ± 3 39 ± 3 −7 a 45 ± 3 34 ± 2* −24 46 ± 3 29 ± 2* −37 a 
Lateral striatum 46 ± 3 29 ± 3* −37 44 ± 3 41 ± 3 −7 c 46 ± 4 30 ± 3* −35 48 ± 4 31 ± 3* −35 a 
Globus pallidus 33 ± 2 20 ± 2 −39 32 ± 2 33 ± 2 −3 a, b, c 32 ± 2 30 ± 2 −6 35 ± 2 23 ± 3* −34 a, c 
Substantia nigra 30 ± 3 20 ± 1* −27 27 ± 3 25 ± 4 −7 28 ± 4 30 ± 2 7 28 ± 2 18 ± 4 −36 
Limbic areas             
Medial septal nucleus 41 ± 3 30 ± 2* −27 39 ± 3 22 ± 2* −44 a 45 ± 2 31 ± 2* −31 48 ± 3 30 ± 2* −38 a 
Lateral septal nucleus 38 ± 3 27 ± 3* −29 40 ± 2 18 ± 2* −55 a, c 37 ± 3 28 ± 3 −24 40 ± 4 27 ± 3* −33 a 
Bed nucleus of the stria terminalis 27 ± 4 18 ± 2* −33 31 ± 2 16 ± 3* −48 a 30 ± 4 20 ± 2 −33 30 ± 2 18 ± 3* −40 a 
Basolateral amygdala 36 ± 3 26 ± 3* −28 36 ± 2 15 ± 2* −58 a, b, c 38 ± 2 27 ± 4 −29 38 ± 2 24 ± 4* −37 a 
Central amygdala 26 ± 2 20 ± 2* −23 25 ± 3 15 ± 2* −40 a 25 ± 2 17 ± 2 −32 24 ± 3 15 ± 2* −38 a 
Local cerebral glucose utilization (LCMRglu), shown as mean ± SEM and percentage change in LCMRglu in 8-OH-DPAT or DOI compared 
with saline-treated mice. n = 8. aMain effect of drug; bmain effect of genotype, cgenotype X drug interaction in 2-way ANOVA, where critical 
F(1,28) value was 4.20 for P ≤ 0.05. *P < 0.05 vs saline in post-hoc analysis. 
In limbic areas, both genotypes decreased LCMRglu significantly (Table 1), but the genotype 
x 8-OH-DPAT interaction in lateral septum (ANOVA: F(1,28) = 4.654, P = 0.040) and 
basolateral amygdala (BLA) (ANOVA: F(1,28) = 4.654, P = 0.040) revealed that the CRFR2-
null mice had a greater response to 5-HT1AR agonist in these areas. Following DOI challenge, 
there was again a main effect of treatment throughout the forebrain (ANOVA: F(1,28) = 4.196 
for P = 0.05) (Table 1). Post-hoc analysis revealed that many brain regions showed a 
significant response to DOI in CRFR2-null mice but not controls (Table 1), suggesting 
greater postsynaptic 5-HT2R responsiveness throughout the forebrain in CRFR2-null mice. 
We then analyzed 5-HT and 5-HIAA content in the components of an anxiety-related 
amygdala-subiculum-septal circuit (Figure 5). There was a main effect of ARS on 5-HT 
content in the intermediate part of the lateral septum (LSI) (ANOVA: F(1,22) = 15.41, P = 
0.0008) and of genotype on the 5-HIAA:5-HT ratio (ANOVA: F(1,22) = 19.460, P = 0.0002). 
There was also a genotype x ARS interaction in subiculum on both 5-HT (ANOVA: F(1,22) = 
5.196, P = 0.033) and 5-HIAA:5-HT ratio (ANOVA: F(1,22) = 10.87, P = 0.004), and a main 
effect of genotype on 5-HIAA:5-HT (ANOVA: F(1,22) = 4.585, P = 0.045). 
Figure 5 5-HT responses to stress are altered in efferent brain regions of CRFR2-null 
mice. 5-HIAA and 5-HT levels as well as 5-HIAA/5-HT ratios are shown in the (A) 
subiculum (S), (B) intermediate part of the lateral septum (LSI), (C) medial septum (MS), 
(D) basolateral amygdala (BLA) and (E) central amygdala (CeA). CRFR2-null mice showed 
differences in basal levels of 5-HT and or 5-HIAA:5-HT ratio in the S and LSI, and a 
differential response to stress in the LSI and BLA. Data expressed as mean ± SEM. N = 8 for 
LCMRglu, ANOVA critical F(1,28) value = 4.196 for P ≤ 0.05, 7.636 for P ≤ 0.01, 13.500 for 
P ≤ 0.001. N = 6 or 7 for 5-HIAA and 5-HT content, ANOVA critical F(1,22) values = 4.301 
for P ≤ 0.05, 7.945 for P ≤ 0.01, 14.380 for P ≤ 0.001. * P < 0.05, ** P < 0.01, *** P < 0.001 
in post-hoc analysis. 
Post-hoc analysis revealed that under basal conditions the 5-HIAA:5-HT ratio was increased 
in CRFR2-null mice (subiculum; t = 3.846, P = 0.001, n = 6: LSI; t = 4.657, P < 0.0001, n = 
7). However, in contrast with the DRN, this was due to lower 5-HT (subiculum; t = 2.474, P 
= 0.022, n = 6-7: LSI; t = 2.759, P < 0.012, n = 7) with unchanged 5-HIAA. In response to 
ARS, 24 h later there was an increase in 5-HT in the LSI of CRFR2-null mice (t = 3.878, P = 
0.0009, n = 6 or 7) and a decrease in the 5-HIAA:5-HT ratio (t = 2.516, P = 0.020, n = 6 or 
7). The genotype x ARS interaction in the subiculum was such that 5-HIAA:5-HT was 
increased by ARS in controls (t = 2.569, P = 0.018, n = 6 or 7), but decreased in CRFR2-null 
mice (t = 2.094, P = 0.049, n = 6 or 7). In the CeA, there was a main effect of ARS 
(ANOVA: F(1,22) = 17.71, P = 0.004) to increase 5-HT content in both genotypes (t = 2.838, P 
= 0.010, n = 6 or 7 for controls; t = 3.113, P = 0.005 for CRFR2-null mice, n = 6 or 7). 5-HT 
levels also increased in the BLA (t = 2.168, P = 0.041, n = 6 or 7) of CRFR2-null mice in 
response to ARS (Figure 5). 
Serotonergic and corticosteroid receptor gene expression are altered in 
response to stress in CRFR2-null mice 
To investigate which factors potentially involved in the processes of adaptation to acute stress 
might be differentially regulated in CRFR2-null mice as compared with controls, SERT 
protein levels (ligand binding) and mRNA levels of serotonergic genes and corticosteroid 
receptors (ISH) were quantified in apposite brain nuclei following ARS or end of CVMS. A 
time of 12 h post-stress was chosen as appropriate, as altered expression of these factors at 
this time has previously been observed by many investigators. Full results are in Additional 
file 1; only key significant differences are presented here. 
In agreement with responses to 8-OH-DPAT, 5-HT1AR mRNA expression did not differ with 
genotype in the hippocampus or amygdala (Additional file 1). No effect of genotype or stress 
was seen in the DRN (Figure 6), but a genotype x stress interaction (ANOVA: F(2,36) = 3.328, 
P = 0.048) whereby decreased expression in control compared with CRFR2-null mice (t = 
2.181, P = 0.036, n = 7) was seen in the MRN following CVMS, and there were trends for 
ARS to reduce 5-HT1AR expression in CRFR2-null mice (t = 1.702, P = 0.098, n = 6 or 7) but 
not controls, and for CVMS to reduce 5-HT1AR expression in controls alone (t = 2.020, P = 
0.052, n = 6 or 7). There was no appreciable effect of genotype on 5-HT2CR mRNA 
expression (Additional file 1). 
Figure 6 Serotonergic and corticosteroid receptor expression are regulated 
differentially in response to stress in CRFR2-null mice. (A) mRNA expression of 5-
HT1AR in the (B) dorsal raphe nucleus (DRN) and (C) median raphe nucleus (MRN); (D) 
tryptophan hydroxylase 2 (TPH2) mRNA in (E) DRN and (F) MRN; (G) serotonin 
transporter (SERT) protein expression in (H) hippocampal CA1, (I) CA2 and (J,K) 
subiculum (S); (L) glucocorticoid receptor (GR) mRNA expression in (M) CA1, (N) CA2 
and (O,P) the paraventricular nucleus (PVN). Data presented as mean ± SEM for mRNA 
levels or densitometry signal (SERT). N = 6 to 8. ANOVA critical F(2,36) value = 3.259 for P 
≤ 0.05, 5.248 for P ≤ 0.01, 8.420 for P ≤ 0.001. # P < 0.05, ## P < 0.01, ### P < 0.001 for 
effect of stress across genotypes. * P < 0.05, ** P < 0.01, *** P < 0.001 in post-hoc analysis. 
ARS increased CRFR2 mRNA expression in whole brain of mice at all times points up to 48 
h post-stress (Q), whereas CVMS decreased CRFR2 expression 7 days after the end of the 
CVMS protocol (R). Data presented as mean ± SEM. N = 8. ANOVA critical F(5,42) value = 
2.438 for P ≤ 0.05, 3.488 for P ≤ 0.01. * P < 0.05, ** P < 0.01 as compared with 0 hours in 
post-hoc analysis or with control group. 
There was a main genotype effect on TPH2 mRNA expression in MRN (ANOVA: F(2,36) = 
5.311, P = 0.027), with increased levels in CRFR2-null mice. Post-hoc analysis detected this 
as significant only between ARS groups (t = 2.080, P = 0.045, n = 6 or 7) (Figure 6). There 
was a main effect of stress on TPH2 in DRN (ANOVA: F(2,36) = 3.684, P = 0.036) across 
genotypes. 
In the hippocampus, there was a main effect of stress on SERT protein expression (CA1 
ANOVA: F(2,36) = 4.106, P = 0.027; CA2 ANOVA: F(2,36) = 4.387, P = 0.020; subiculum 
ANOVA: F(2,36) = 8.474, P = 0.001), owing to increased expression after the end of CVMS, 
only reaching statistical significance in CRFR2-null mice (CA1 t = 2.151, P = 0.038, n = 7 or 
8; CA2 t = 2.139, P = 0.026, n = 7 or 8; subiculum t = 3.490, P = 0.0013, n = 7 or 8) and not 
in controls (Figure 6). There were no effects of genotype or stress on SERT expression in the 
amygdala (Additional file 1). 
Expression of GR mRNA showed differential effects between brain regions and genotypes 
(Figure 6). In the dorsal hippocampus, there was a trend towards higher GR expression in 
CRFR2-null mice (CA1 ANOVA: F(2,36) = 3.976, P = 0.054; CA2 ANOVA: F(2,36) = 4.008, P 
= 0.067). There was a main effect of stress (ANOVA: F(2,36) = 7.312, P = 0.002) with both 
ARS and CVMS reducing expression in CA1 of CRFR2-null mice (ARS t = 2.420, P = 
0.021, n = 7 or 8; CVMS t = 2.962, P = 0.005, n = 7 or 8), but only CVMS had a significant 
effect in controls (t = 2.962, P = 0.043, n = 6 or 7). In CA2, only CVMS had an effect to 
reduce GR expression, and this was only significant in CRFR2-null mice (t = 2.725, P = 
0.010, n = 7 or 8). In the paraventricular nucleus (PVN) there was a main effect of genotype 
(ANOVA: F(2,36) = 6.788, P = 0.003) with CRFR2-null mice having lower GR mRNA 
expression, although this was not significant within treatment groups in post-hoc analysis. 
There was a main effect of stress (ANOVA: F(2,36) = 4.974, P = 0.032); post-hoc analysis 
showed increased GR following CVMS, but only reaching significance in CRFR2-null mice 
(t = 2.341, P = 0.025, n = 7 or 8). Expression of MR mRNA was not regulated by stress or 
genotype in any brain region examined (Additional file 1). Finally, CRFR2 mRNA levels, as 
quantified by qPCR, were increased over a time period of 3 to 48 hours post-ARS (ANOVA: 
F(5,42) = 3.750, P = 0.007) but were decreased following CVMS (t = 2.164, P = 0.047, n = 8) 
(Figure 6). 
Discussion 
This study extends the evidence regarding the importance of CRFR2 in mediating the 
processes towards successful behavioural recovery in the period following stress, and 
moreover demonstrates that CRFR2 is engaged in the control of serotonergic function during 
the same time frame. It further characterizes the stress-sensitive phenotype of CRFR2-null 
mice [50,51,62] and reveals fundamental disturbances within components of their 
serotonergic system. 
In contrast with original reports of increased basal levels of anxiety [50,51], in our hands, 
similar to the findings of Coste et al. [62], CRFR2-null mice do not show increased anxiety-
like behaviour compared to controls until 24 h after exposure to a prior acute stressor. This 
discrepancy could be due to differing phenotypes of the three independently generated strains 
of CRFR2-null mice, or factors such as age or husbandry. However, the mice in this study are 
the same strain as reported with increased anxiety by Bale et al. [50] and an anxious 
phenotype was described for both group- [50] and singly [51] housed CRFR2-null mice from 
9 [40] to 24 [50] weeks of age, but not at 16 weeks [62], meaning that these factors are 
unlikely to explain the inconsistency. This study indicates the need for a prior stress for 
increased anxiogenesis in CRFR2-null mice, so an alternative explanation is that mice in 
previous studies might have been inadvertently previously stressed, for example, by a prior 
behavioural test. This time course of the behavioural effects of ARS led us to conclude that 
CRFR2 has a key role in the processes leading to behavioural recovery in the hours following 
exposure to a stressor. 
While CRFR2-null mice in our study appear to be in a maladaptive state at 24 hours 
following an acute stress, CRFR2-null mice exposed to CVMS are not more anxious than 
controls. It could be interpreted from this that CRFR2-null mice have the ability to cope 
successfully with this more chronic stress, but it is more likely that both CRFR2-null mice 
and controls are affected adversely by CVMS, while CRFR2-null mice show an exaggerated 
response to a single acute stressor. Such stressors might release CRF sufficient to recruit 
CRFR2 [20], which mediate successful stress coping in normal mice [63]. Alternatively, 
increased CRFR1 signalling in response to stress might occur; increased CRF expression in 
the amygdala and PVN of CRFR2-null mice has been reported [50]. However, the time frame 
of delayed anxiogenesis in CRFR2-null mice does not correlate with the expected rapid 
release of CRF in response to acute stress and its subsequent negative feedback. The time 
interval required for CRFR2-null mice to acquire this anxiety trait suggests that the processes 
are indirect, and the serotonergic system is an obvious candidate. 
Exogenous CRF administered to the DRN inhibits firing of 5-HT neurons via CRFR1 
[15,18], while Ucns or higher levels of CRF increase firing via CRFR2 [32-36]. The raphe 
nuclei receive inputs from both CRF and Ucn1 neurons [14,15,29], which may therefore 
regulate serotonergic raphe function physiologically. In support of this hypothesis, CRFR2-
null mice show altered 5-HT/5-HIAA content in the DRN, LSI, subiculum, CeA and BLA 24 
h after ARS, whereas control mice showed a clear change only in 5-HT content of the CeA. 
Recent studies of mice with genetically altered Ucn levels have shown that 5-HT function is 
dysregulated in these models [39-41] and that CRFR2-null mice show greater sensitivity to 
elevation of 5-HT levels by pharmacological means, an observation suggested to be linked to 
their stress-sensitive phenotype [64]. Notably, mice deficient in all three Ucns do indeed 
show a similar phenotype [41] to our observations in CRFR2-null mice, with increased 
anxiety-like behaviour and dysregulated activity within 5-HT circuits 24 h following ARS, 
again evidencing the importance of CRFR2 here. 
Interestingly, CRFR2-null mice show decreased basal neuronal metabolic activity in the 
raphe nuclei. This is typically interpreted as evidence of decreased 5-HT firing activity levels, 
as while both 5-HT and GABAergic neurons are important functionally here, GABAergic 
neurons are present at only 10% of the number of 5-HT neurons [65]. This is an unusual 
finding under basal conditions in our experience and could be due to increased raphe 5-
HT1AR inhibitory autoreceptor activity, altered 5-HT1AR modulation of raphe GABAergic 
interneurons that express both CRFR2 and 5-HT1AR, or by inhibition from forebrain 
postsynaptic receptors including 5-HT1AR and 5-HT2R [66-69]. Increased sensitivity of 
structures throughout the forebrain to 5-HT2R agonists and to 5-HT1AR in some limbic 
structures in CRFR2-null mice suggests that postsynaptic receptor responsiveness is 
increased, and thus the latter mechanism may be significant. A shift towards unopposed 
CRFR1 activity in the raphe nuclei of CRFR2-null mice could also be a significant factor in 
mediating these effects or directly inhibiting 5-HT neuronal activity. Uncontrollable stress, 
which activates DRN serotonergic neurons [38], is associated with a functional 
desensitization of 5-HT1AR [70]. We observed no significant differences in 5-HTR 
expression in the DRN of CRFR2-null mice and so it is likely that these effects are also 
mediated by decreased internalization and desensitization of receptors [71], providing a 
mechanism for potentially very dynamic responses to stress. Detailed electrophysiological 
studies would be required to resolve the mechanism further. 
In contrast with forebrain structures, the lack of LCMRglu response in the raphe nuclei to 5-
HTR agonists in CRFR2-null mice suggests tonic inhibition of neuronal activity here may be 
close to maximal under basal conditions. The response to 5-HT1AR agonist in extrapyramidal 
brain areas receiving projections from the DRN [72,73] but lacking their own 5-HT1AR 
[74,75] was also attenuated. Thus CRFR2 appear to be required for maintaining normal basal 
neuronal activity in the raphe nuclei and, in particular, for the balance of 5-HT1AR function 
here. 
CRFR2 are present in both the DRN and the MRN [11,13]. However, studies of stress 
biology have largely concentrated on the DRN, and so to relate this altered raphe function to 
the CRFR2-null behavioural phenotype, we examined 5-HT responses to stress in the DRN 
and associated anxiety-related nuclei. Concentrations of 5-HIAA and the 5-HIAA:5-HT ratio 
were elevated in CRFR2-null mice under baseline conditions within the caudal subregion of 
the DRN (DRC), and these effects approached significance in the adjacent dorsal subregion 
(DRD). The DRD and DRC mediate CRF receptor responses and are considered to be 
anxiety-related subregions of the DRN based on anatomical and functional criteria [76,77]. 
For example, they are activated by anxiogenic drugs [78], CRF-related peptides in vivo 
[33,79] and in vitro [80], inescapable shock [70], noise stress [80], social defeat [81], the 
avoidance task on the elevated T-maze [82], acoustic startle [83] and anxiety due to prior 
experience of intimate partner violence [84]. In support of the specificity of these anxiety-
related effects on DRD/DRC serotonergic systems, in none of these studies were serotonergic 
neurons in the adjacent ventrolateral part of the DRN activated. Elevation of 5-HIAA and 5-
HIAA:5-HT ratios in the DRC could be due to an organizational difference in 5-HT systems 
as a consequence of CRFR2-null phenotype, or to differential activity that develops later in 
life. In either case, DRC neurons appear to have altered baseline activity in adult CRFR2 null 
mice, which may reflect a vulnerability to increased anxiety states. 
Despite lower 5-HT content in efferent stress-related nuclei under unstressed conditions in 
CRFR2-null mice, stress had a greater effect on their 5-HT content at 24 h, in keeping with 
their stress-sensitive phenotype. This was particularly evident in LSI, which receives 
significant 5-HT projections from the caudal DRN [85,86], in the subiculum and, to a lesser 
extent, in the CeA. The subiculum is a key structure in inhibiting the hypothalamic-pituitary-
adrenal axis (HPAA) during termination of the stress response [87] and so altered function 
here might relate to the higher responsiveness of the HPAA in CRFR2-null mice following 
acute stress [50,62]. 
Not all anxiety-related nuclei examined showed such changes. We found no differences in the 
LCMRglu of the bed nucleus of the stria terminalis (BNST) between control and CRFR2-null 
mice at either baseline or in response to 8-OH-DPAT or DOI challenge. This was 
unexpected, given the pivotal role of the BNST in the control of anxiety states [88]. However, 
the serotonergic dysregulation in CRFR2-null mice may be downstream of the BNST which 
projects strongly to the DRD/DRC region [89], where CRFR2 are abundant [12,13]. 
Overexpression of CRF in the BNST induces a decrease in CRFR2 binding selectively in the 
DRD/DRC [90] and so it may be that the observed effects in CRFR2-null mice are primarily 
mediated here. 
5-HT firing activity is generally increased by stress [20] and negative feedback to the DRN 
ultimately restores balance [66-69,71], as evidenced by essentially unchanged 5-HT and 5-
HIAA levels in control mice at 24 h following ARS. It has been previously reported that 
CRFR2-null mice show greater sensitivity to 5-HT modulation of stress-induced behaviours 
[64]. The pattern of increased responses in CRFR2-null mice to both 5-HT1AR and 5-HT2R 
receptor agonists in areas expressing postsynaptic receptors is in keeping with this finding. 
The LSI and BLA are key components of the limbic stress circuitry that were more 
responsive to 5-HT1AR agonist in CRFR2-null mice. This might therefore relate to their 
stress-sensitive phenotype and indicate a role for these structures in stress recovery. 
The MRN has been implicated in mediating a delayed coping response following fear 
behaviour induced by CRF in the DRN [35,91]. A delayed increase in 5-HT in the mPFC 
mediated by CRFR2 in MRN is associated with cessation of intra-DRN CRF-induced 
freezing behaviour [91] and is therefore proposed to mediate stress resilience effects [92]. In 
CRFR2-null mice, the CRFR2-mediated surges in 5-HT neuronal firing from DRN and MRN 
cannot occur, and unopposed CRFR1-mediated inhibition in DRN might further contribute to 
this [15,18]. The normal 5-HT response in mPFC occurs one to two hours after intra-DRN 
CRFR2 receptor activation [35,91], and we infer that the maladaptive state in CRFR2-mice 
develops after the peak of this CRFR2-induced increase in mPFC 5-HT and by 24 h after the 
stress. Thus, we propose that this delayed activity in efferent 5-HT neurons, which is critical 
for successful adaptation to acute stress, is disrupted in CRFR2-null mice. The consequences 
for CRFR2-null mice beyond 24 h are unknown, but unlike controls, 5-HT levels at this time 
point are increased from basal levels in several limbic nuclei, indicating that homeostasis has 
not been restored It is feasible that a lack of negative feedback within the 5-HT system due to 
the failure of CRFR2-mediated 5-HT activity might contribute to this. 
Therefore, we propose that a rapid and highly regulated increase in CRFR2 signalling in 
response to acute stress, the resultant increase in efferent 5-HT activity and subsequent 
negative feedback to restore homeostasis are important for a normal and successful coping 
response. The delayed increase in 5-HT in mPMC is of key importance. Without this 
orchestrated response, CRFR2-null mice do not respond to stress appropriately, and there is 
prolonged anxiety that might account for their well-recognized anxiety phenotype. This 
proposed model is presented in Figure 7. There is significant evidence for a role for the MRN 
in stress recovery [91,92], and this model is consistent with our observation that LCMRglu is 
lower under basal conditions in the MRN of CRFR2-null mice while the robust elevation of 
TPH2 mRNA in CRFR2-null MRN might be a compensatory response to a lack of CRFR2 
activation here. More detailed analysis of the dynamics of CRF and 5-HT processes in this 
time frame and beyond in appropriate subregions of the raphe nuclei, and consideration of the 
roles of other mediators of the stress response in CRFR2-null mice, are required to 
substantiate this further. 
Figure 7 Proposed model for development of prolonged anxiety following acute stress in 
CRFR2-null mice. Following acute stress in control mice (A) CRF acting at CRFR1 in the 
limbic forebrain produces immediate anxiety. High levels of CRF and potentially Ucn1 
activate CRFR1 and more abundant CRFR2 in the DRN with a net effect to promote early 
firing of efferent 5-HT neurons to limbic nuclei. Activation of CRFR2 in the MRN promotes 
delayed 5-HT release in the mPFC at 1 to 2 h, which acts at 5-HT1AR to mediate successful 
coping and anxiolysis by 24 h. Negative feedback in the 5-HT system restores homeostasis 
by 24 h. (B) In CRFR2-null mice, the CRFR2-mediated increase in 5-HT firing cannot occur 
and unopposed CRFR1 activity might inhibit 5-HT neuronal firing in limbic nuclei even 
further. Absence of negative feedback within the 5-HT system contributes to the increased 5-
HT levels observed in limbic areas at 24 h. The temporal dynamics of the 5-HT system 
following acute stress are dysregulated and homeostasis has not been restored. Crucially, the 
delayed 5-HT activity in mPFC is disrupted and successful coping has not occurred, resulting 
in prolonged anxiety. 
Owing to the number of mediators involved in stress responses and the complex interactions 
among them, other factors in addition to the serotonergic system are likely to be modified in 
CRFR2-null mice in the hours following stress exposure, which might have implications for 
the longer term. Indeed Ucn1 expression in the Edinger-Westphal nucleus and CRF in CeA 
(but not the PVN) are increased in CRFR2 mice [50], which may be a developmental 
compensatory change that is also responsible at least in part for their phenotype. Expression 
of CRFR1 is, however, unaltered. We found that changes in serotonergic and corticosteroid 
receptor gene expression in response to stress were generally greater in CRFR2-null mice, 
again in keeping with their stress-sensitive behavioural phenotype. CRFR2-null mice have 
normal basal HPAA activity, but higher responsiveness following acute stress [50,62]. 
Hence, changes such as the observed greater stress-induced increases in hippocampal SERT 
levels in CRFR2-null mice may be mediated by glucocorticoids [93,94], adding potentially 
further complexity to the relationship between CRFR2 and 5-HT function. Stress also 
downregulated hippocampal GR mRNA to a greater degree in CRFR2-null mice, potentially 
reflecting this expected HPAA hyperactivation. CRFR2-null mice also had lower basal GR 
expression in the PVN, possibly reflecting chronically higher HPAA tone, and CVMS 
unexpectedly increased this. Discordant regulation of GR expression in the hippocampus and 
PVN has been reported previously [95,96], with upregulation of GR by stress suggested to 
maintain glucocorticoid signalling to limit HPAA responses during prolonged stress. 5-HT 
also regulates GR expression, and this may be mediated through TPH2 activity, in order to 
regulate HPAA activity [97]. Both TPH2 and 5-HT1AR mRNAs in MRN were differentially 
expressed in CRFR2-null mice. TPH2 mRNA levels in MRN were higher in CRFR2-null 
mice, and there may be altered afferent control of DRN activity from here [98], suggesting 
that the MRN should be more carefully considered in future studies of CRFR2 function. 
Given this proposed role of CRFR2, we might expect expression to be regulated by stress 
exposure. We found expression to increase, reaching a maximum at 3 to 12 h post-ARS and 
subsequently declining, an effect similar to that seen for CRFR1 when acutely exposed to 
ligand [99], while chronic stress decreased CRFR2 mRNA expression in this and a previous 
study [100]. Others have observed lower CRFR2 expression in adult rats subjected to 
maternal deprivation or in genetically stress-sensitive rodent strains [101,102], suggesting 
that CRFR2 downregulation has the potential to be permanent in anxious or stress-sensitive 
animals. The interesting exceptions are where CRFR2 is increased by chronically elevated 
levels of CRF [103] or corticosterone [104], or in a model of maladaptive post-traumatic 
stress disorder-like behaviour [105]. We hypothesize that while increased CRFR2 activity is 
required for successful recovery from stress and subsequent downregulation is a normal 
adaptive response associated with healthy coping, that ongoing hyperactivity of CRFR2 
might be associated with a maladaptive stress response. The role of CRFR2 in mediating 
learned helplessness in response to uncontrollable stress has implicated CRFR2 activity in the 
development of maladaptive behavioural responses [38,79]. However equally, CRFR2 
upregulation might be an appropriate secondary adaptation to a chronic stress. This issue 
requires further investigation, to assess whether CRFR2 is a potential target in stress-related 
psychiatric disorders. 
In this study, 5-HT function in the lateral septum and subiculum, sites linked with anxiety as 
well as the neural circuitry of reward and addiction [106-108], was particularly altered. 
Dysregulated serotonergic function has long been linked to stress-related psychopathologies 
[109,110] and direct effects of Ucns on CRFR2 in LSI have been observed in rodent models 
of these disorders; hence, CRFR2 may play an important role in these processes [111-113]. 
Conclusions 
While the role of CRFR2 in stress recovery was proposed some time ago [63,114], this study 
provides new information regarding the mechanisms by which this may be mediated and 
highlights the importance in the immediate post-stress period. This has implications for the 
pathophysiology of psychiatric conditions associated with acute stress exposure, such as post-
traumatic stress disorder, reactive depression and relapse to substance abuse. As evidence 
continues to emerge that CRFR2 may mediate its effects on stress primarily through 5-HT, 
the potential for involvement in further mood disorders and ultimately for therapeutic 
targeting is clear. 
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